Cardiac	cardiac	O	DISEASE	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
observed	observed	O	O	O	O
in	in	O	O	O	O
association	association	O	O	O	O
with	with	O	O	O	O
high-dose	high-dose	O	O	O	O
cyclophosphamide-based	cyclophosphamide-based	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
for	for	O	O	O	O
metastatic	metastatic	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
.	.	O	O	O	O

INTRODUCTION	introduction	O	O	O	O
:	:	O	O	O	O
Cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
an	an	O	O	O	O
alkylating	alkylating	O	O	O	O
agent	agent	O	O	O	O
given	given	O	O	O	O
frequently	frequently	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
component	component	O	O	O	O
of	of	O	O	O	O
many	many	O	O	O	O
conditioning	conditioning	O	O	O	O
regimens	regimens	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
high	high	O	O	O	O
doses	doses	O	O	O	O
,	,	O	O	O	O
its	its	O	O	O	O
nonhematological	nonhematological	O	O	O	O
dose-limiting	dose-limiting	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
is	is	O	O	O	O
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

STUDY	study	O	O	O	O
DESIGN	design	O	O	O	O
:	:	O	O	O	O
We	we	O	O	O	O
combined	combined	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
melphalan	melphalan	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
high-dose	high-dose	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
thiotepa	thiotepa	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
carboplatin	carboplatin	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
triple	triple	O	O	O	O
sequential	sequential	O	O	O	O
high-dose	high-dose	O	O	O	O
regimen	regimen	O	O	O	O
for	for	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
metastatic	metastatic	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Analysis	analysis	O	O	O	O
was	was	O	O	O	O
performed	performed	O	O	O	O
on	on	O	O	O	O
61	61	O	O	O	O
women	women	O	O	O	O
with	with	O	O	O	O
chemotherapy-responsive	chemotherapy-responsive	O	O	O	O
metastatic	metastatic	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
receiving	receiving	O	O	O	O
96-h	96-h	O	O	O	O
infusional	infusional	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
part	part	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
triple	triple	O	O	O	O
sequential	sequential	O	O	O	O
high-dose	high-dose	O	O	O	O
regimen	regimen	O	O	O	O
to	to	O	O	O	O
assess	assess	O	O	O	O
association	association	O	O	O	O
between	between	O	O	O	O
presence	presence	O	O	O	O
of	of	O	O	O	O
peritransplant	peritransplant	O	O	O	O
congestive	congestive	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
(	(	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
following	following	O	O	O	O
pretreatment	pretreatment	O	O	O	O
characteristics	characteristics	O	O	O	O
:	:	O	O	O	O
presence	presence	O	O	O	O
of	of	O	O	O	O
electrocardiogram	electrocardiogram	O	O	O	O
(	(	O	O	O	O
EKG	ekg	O	O	O	O
)	)	O	O	O	O
abnormalities	abnormalities	O	O	O	O
,	,	O	O	O	O
age	age	O	O	O	O
,	,	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
,	,	O	O	O	O
prior	prior	O	O	O	O
cardiac	cardiac	O	O	O	O
history	history	O	O	O	O
,	,	O	O	O	O
smoking	smoking	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
diabetes	diabetes	O	DISEASE	OTHERS	I
mellitus	mellitus	O	DISEASE	OTHERS	I
,	,	O	O	O	O
prior	prior	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
anthracyclines	anthracyclines	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
left-sided	left-sided	O	O	O	O
chest	chest	O	O	O	O
irradiation	irradiation	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Six	six	O	O	O	O
of	of	O	O	O	O
61	61	O	O	O	O
women	women	O	O	O	O
(	(	O	O	O	O
10	10	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
developed	developed	O	O	O	O
clinically	clinically	O	O	O	O
reversible	reversible	O	O	O	O
grade	grade	O	O	O	O
3	3	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
following	following	O	O	O	O
infusional	infusional	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
with	with	O	O	O	O
a	a	O	O	O	O
median	median	O	O	O	O
percent	percent	O	O	O	O
decline	decline	O	O	O	O
in	in	O	O	O	O
ejection	ejection	O	O	O	O
fraction	fraction	O	O	O	O
of	of	O	O	O	O
31	31	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

Incidence	incidence	O	O	O	O
of	of	O	O	O	O
transient	transient	O	O	O	O
cyclophosphamide-related	cyclophosphamide-related	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
(	(	O	O	O	O
10	10	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
is	is	O	O	O	O
comparable	comparable	O	O	O	O
to	to	O	O	O	O
previous	previous	O	O	O	O
recorded	recorded	O	O	O	O
literature	literature	O	O	O	O
.	.	O	O	O	O

Older	older	O	O	O	O
age	age	O	O	O	O
was	was	O	O	O	O
significantly	significantly	O	O	O	O
correlated	correlated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
development	development	O	O	O	O
;	;	O	O	O	O
with	with	O	O	O	O
median	median	O	O	O	O
ages	ages	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
entire	entire	O	O	O	O
group	group	O	O	O	O
and	and	O	O	O	O
for	for	O	O	O	O
patients	patients	O	O	O	O
developing	developing	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
of	of	O	O	O	O
45	45	O	O	O	O
and	and	O	O	O	O
59	59	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
association	association	O	O	O	O
was	was	O	O	O	O
found	found	O	O	O	O
with	with	O	O	O	O
other	other	O	O	O	O
pretreatment	pretreatment	O	O	O	O
characteristics	characteristics	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
As	as	O	O	O	O
a	a	O	O	O	O
result	result	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
findings	findings	O	O	O	O
,	,	O	O	O	O
oncologists	oncologists	O	O	O	O
should	should	O	O	O	O
carefully	carefully	O	O	O	O
monitor	monitor	O	O	O	O
fluid	fluid	O	O	O	O
balance	balance	O	O	O	O
in	in	O	O	O	O
older	older	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Routine	routine	O	O	O	O
EKG	ekg	O	O	O	O
monitoring	monitoring	O	O	O	O
during	during	O	O	O	O
infusional	infusional	O	O	O	O
cyclophosphamide	cyclophosphamide	CHEMICALS	O	OTHERS	I
did	did	O	O	O	O
not	not	O	O	O	O
predict	predict	O	O	O	O
CHF	chf	O	DISEASE	OTHERS	I
development	development	O	O	O	O
.	.	O	O	O	O

